News and Trends 31 Aug 2018 Vertex Partners Oxford Genome Analysis Firm To Develop New Personalized Therapies …and royalty payments if new targets discovered during the collaboration that reach clinical development. The US biotech is behind the cystic fibrosis drug Kaldeco (ivacaftor). This therapy is the first… August 31, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Ionis presents positive study results at International Symposium on amyloidosis …quality of life compared to the external placebo group. Eplontersen demonstrated a favorable safety and tolerability profile. In the study, the rate of treatment emergent adverse events (TEAEs) in the… September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 The role of long-read sequencing in validating CRISPR outcomes …on each occasion. After repeating the same experiment four times, they found no consistency in outcomes, saying, “Each biological replicate differed substantially, despite a large number of unique deletion events… October 20, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Alentis reports positive results from fibrosis study …adverse events were recorded. A multiple ascending dose phase 1 study is ongoing, the results of which will be reported in Q1 2023. Encouraging data for Alentis Therapeutics’ lead program… January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 AstraZeneca non-small cell lung cancer drug meets primary endpoint …majority being low grade. Some Grade 5 events were observed. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo…. July 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 1 Feb 2023 Foundation for the National Institutes of Health: partnering to tackle cancer …techniques, animal modeling, clinical genomics, systems biology, project and team management, and strategy consulting. Labiotech asked Dr Adam about the organization’s role in the fight against cancer. What does the… February 1, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2023 New therapy for prevention and treatment of COVID-19 …a novel, highly potent, anti-S2 camelid single-domain antibody, discovered at the VIB-UGent Center for Medical Biotechnology, which was developed as a candidate drug molecule by ExeVir Bio as XVR013. It… March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 2 May 2025 From pandemic spotlight to post-COVID crossroads: What happened to these biotech players? …and risk was carried by smaller biotech players suddenly thrown onto the global stage. For a brief moment, it seemed like these companies might reshape the pharmaceutical landscape for good…. May 2, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2017 Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor …belongs to the difficult-to-drug class of GPCRs and binds the anti-inflammatory molecule adenosine, whose expression is often increased within the tumor microenvironment. By stimulating A2A receptors, adenosine prevents T-cells within… April 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2023 Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Table of contents The latest biotech news… December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2020 Universal Flu Vaccines Yield Second Clinical Failure This Year …in January. Last week proved a major setback for the Israeli biotech BiondVax. The company’s vaccine — designed to protect against multiple strains of flu — failed in phase III…. October 29, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 28 Jan 2017 Microbes Control the Massive Turbine Hall at London’s Tate Modern …yeast. In turn, the food the microbes receive alters their movement patterns, which are measured and used by computer software to control all the events going on at the hall…. January 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email